Journal of the American Society of Hypertension
Volume 2, Issue 3 , Pages 165-172 , May 2008

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors

  • Ronald D. Smith, MD

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • ,
  • Hiroshi Yokoyama, MD, PhD

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • ,
  • David B. Averill, PhD

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • ,
  • Ernesto L. Schiffrin, MD, PhD

      Affiliations

    • Department of Medicine, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • ,
  • Carlos M. Ferrario, MD

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
    • Corresponding Author InformationCorresponding author: Carlos M. Ferrario, MD, Janeway Clinical Sciences Building, 5th Floor, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157. Tel: 336-716-0757; fax: 336-716-6644.

Received 29 August 2007 ,Revised 8 November 2007

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by an unrestricted grant and study medications from Daiichi Sankyo, Inc. The authors gratefully acknowledge grant support, in part, provided by Unifi, Inc., Greensboro, NC, and the Farley-Hudson Foundation, Jacksonville, NC.

 Conflict of interest: none.

PII: S1933-1711(07)00243-4

doi: 10.1016/j.jash.2007.11.001

Journal of the American Society of Hypertension
Volume 2, Issue 3 , Pages 165-172 , May 2008

Article Tools

* Image Usage & Resolution